1211-STING Unlocks CD4+ T Cell Immunity in Pancreatic Cancer

Recent research indicates that pancreatic ductal adenocarcinoma, a typically treatment-resistant cancer, can be successfully managed by combining checkpoint blockade with STING-mediated immune stimulation. This study demonstrates that a triple therapy involving anti-PD-1, anti-CTLA-4, and a STING agonist triggers an unconventional immune response independent of the usual cytotoxic CD8+ T cells. Instead, the treatment activates cDC2 dendritic cells, which migrate to lymph nodes to prime CD4+ T cells for tumor destruction. These specialized helper cells then release the cytokine IFN-γ to eliminate cancerous growth throughout the body. By pivoting focus toward the cDC2-CD4+ T cell axis, scientists may have found a new way to overcome the immunosuppressive environment that makes pancreatic cancer so lethal. These findings offer a hopeful clinical strategy for patients who do not respond to traditional immunotherapies.References:Kruse B, Leonhardt B P, Böttcher J P. STING unlocks CD4⁺ T cell immunity in pancreatic cancer[J]. Cancer Cell, 2026.前往小宇宙评论区与主播互动